Literature DB >> 8326780

Health care CBA/CEA: an update on the growth and composition of the literature.

A Elixhauser1, B R Luce, W R Taylor, J Reblando.   

Abstract

Cost-benefit (CBA) and cost-effectiveness analyses (CEA) are methods that enumerate the costs and consequences associated with health-related technologies, services, and programs. This article examines the trends in published CBA and CEA of personal health services from 1979 through 1990. It is based on a bibliography that was compiled to help address the immense need for information on the variation and effectiveness of medical practices, particularly as researchers expand their analysis to a study of the cost effectiveness of medical and surgical interventions, health care technologies, preventive practices, and other health programs. A systematic search was conducted for all articles under the heading "cost-benefit analysis" (which includes cost-effectiveness analysis) and "costs and cost analysis." Data sources included the MEDLARS (National Library of Medicine) database, other bibliographies in specialized areas, reference lists in key articles, and contacts with researchers in the field. All titles and abstracts were scanned to determine if the articles pertained to personal health services and if both costs and consequences were assessed. If both criteria were met, the article was included in the bibliography. This search resulted in 3,206 eligible CBA/CEA publications from 1979 through 1990. The publications were subdivided into two major categories: reports of studies and "other" publications, including reviews, descriptions of methodology, letters, and editorials. Reports of studies and "other" publications were classified into approximately 250 different topic areas. The studies were further classified by parameters, such as study type, publication vehicle, and medical function. This article describes the results of this classification and describes trends during 1979 to 1990 compared with 1966 to 1978. The classification of study reports and "other" publications into 250 topic areas is presented in Appendix A. The entire bibliography is reproduced in Appendix B. Detailed tables of findings are presented in Appendix C, and the results are illustrated graphically in Appendix D. Appendix E provides the coding scheme used in the bibliography's data base.

Entities:  

Mesh:

Year:  1993        PMID: 8326780     DOI: 10.1097/00005650-199307001-00001

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  24 in total

Review 1.  Benefit valuation in economic evaluation of cancer therapies. A systematic review of the published literature.

Authors:  J Brown; M Sculpher
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

2.  The problem of protocol driven costs in pharmacoeconomic analysis.

Authors:  D Coyle; K M Lee
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

Review 3.  Why training is the key to successful guideline implementation.

Authors:  A D Paltiel; P J Neumann
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

4.  A qualitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey.

Authors:  Hans-Martin Späth; Marie Charavel; Magali Morelle; Marie-Odile Carrere
Journal:  Pharm World Sci       Date:  2003-12

5.  How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?

Authors:  Bruce R Schackman; Heather Taffet Gold; Patricia W Stone; Peter J Neumann
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 6.  Statistical versus quantitative significance in the socioeconomic evaluation of medicines.

Authors:  B J O'Brien; M F Drummond
Journal:  Pharmacoeconomics       Date:  1994-05       Impact factor: 4.981

7.  Economic evaluation of influenza vaccination and economic modelling. Can results be pooled?

Authors:  T Jefferson; V Demicheli
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 8.  Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.

Authors:  D Coyle
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

9.  Assessing the economic value of a new antidepressant. A willingness-to-pay approach.

Authors:  B J O'Brien; S Novosel; G Torrance; D Streiner
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

10.  Optimal search strategies for detecting health services research studies in MEDLINE.

Authors:  Nancy L Wilczynski; R Brian Haynes; John N Lavis; Ravi Ramkissoonsingh; Alexandra E Arnold-Oatley
Journal:  CMAJ       Date:  2004-11-09       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.